BARD1 is altered in 0.67% of prostate carcinoma patients with BARD1 Loss present in 0.06% of all prostate carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 17 clinical trials for prostate carcinoma, of which 14 are open and 3 are closed. Of the trials that contain BARD1 Loss and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [5].

Olaparib has evidence of efficacy in patients with BARD1 Loss in prostate carcinoma [5].

BARD1 is altered in 1.56% of malignant solid tumor patients with BARD1 Loss present in 0.04% of all malignant solid tumor patients [4].

BARD1 Loss is an inclusion criterion in 31 clinical trials for malignant solid tumor, of which 25 are open and 6 are closed. Of the trials that contain BARD1 Loss and malignant solid tumor as inclusion criteria, 13 are phase 1 (10 open), 7 are phase 1/phase 2 (4 open), and 11 are phase 2 (11 open) [5].

BARD1 is altered in 1.06% of breast carcinoma patients with BARD1 Loss present in 0.04% of all breast carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 20 clinical trials for breast carcinoma, of which 16 are open and 4 are closed. Of the trials that contain BARD1 Loss and breast carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [5].

BARD1 is altered in 1.21% of ovarian carcinoma patients with BARD1 Loss present in 0.05% of all ovarian carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain BARD1 Loss and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

BARD1 is altered in 0.67% of prostate adenocarcinoma patients with BARD1 Loss present in 0.06% of all prostate adenocarcinoma patients [4].

BARD1 Loss is an inclusion criterion in 16 clinical trials for prostate adenocarcinoma, of which 15 are open and 1 is closed. Of the trials that contain BARD1 Loss and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 13 are phase 2 (12 open), and 2 are phase 3 (2 open) [5].

BARD1 Loss is an inclusion criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain BARD1 Loss and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

BARD1 Loss is an inclusion criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain BARD1 Loss and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

BARD1 is altered in 0.79% of adenocarcinoma of the gastroesophageal junction patients [4].

BARD1 Loss is an inclusion criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain BARD1 Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [5].

BARD1 is altered in 1.19% of pancreatic adenocarcinoma patients [4].

BARD1 Loss is an inclusion criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain BARD1 Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

BARD1 is altered in 1.49% of gastric carcinoma patients with BARD1 Loss present in 0.13% of all gastric carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BARD1 Loss and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.91% of non-small cell lung carcinoma patients with BARD1 Loss present in 0.02% of all non-small cell lung carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 5 clinical trials for non-small cell lung carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BARD1 Loss and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

BARD1 is altered in 1.62% of small cell lung carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BARD1 Loss and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [5].

BARD1 is altered in 2.59% of urothelial carcinoma patients with BARD1 Loss present in 0.12% of all urothelial carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BARD1 Loss and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [5].

BARD1 is altered in 3.21% of endometrial carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BARD1 Loss and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

BARD1 is altered in 0.89% of soft tissue sarcoma patients with BARD1 Loss present in 0.16% of all soft tissue sarcoma patients [4].

BARD1 Loss is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain BARD1 Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

BARD1 is altered in 1.5% of gastric adenocarcinoma patients with BARD1 Loss present in 0.13% of all gastric adenocarcinoma patients [4].

BARD1 Loss is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain BARD1 Loss and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

BARD1 is altered in 1.35% of high grade ovarian serous adenocarcinoma patients with BARD1 Loss present in 0.07% of all high grade ovarian serous adenocarcinoma patients [4].

BARD1 Loss is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BARD1 Loss and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

BARD1 is altered in 0.92% of cervical carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BARD1 Loss and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

BARD1 is altered in 2.18% of colorectal carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BARD1 Loss and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].

BARD1 is altered in 1.16% of pancreatic carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BARD1 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

BARD1 is altered in 0.44% of osteosarcoma patients with BARD1 Loss present in 0.44% of all osteosarcoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 Loss and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

BARD1 is altered in 2.74% of bladder urothelial carcinoma patients with BARD1 Loss present in 0.14% of all bladder urothelial carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 Loss and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

BARD1 is altered in 0.38% of non-hodgkin lymphoma patients with BARD1 Loss present in 0.07% of all non-hodgkin lymphoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BARD1 Loss and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

BARD1 is altered in 0.35% of clear cell renal cell carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 Loss and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

BARD1 is altered in 1.83% of esophageal adenocarcinoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 Loss and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.66% of esophageal carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 Loss and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

BARD1 is altered in 0.5% of gastrointestinal stromal tumor patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain BARD1 Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.37% of head and neck carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.31% of head and neck squamous cell carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BARD1 Loss and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

BARD1 is altered in 2.87% of melanoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 Loss and melanoma as inclusion criteria, 2 are phase 2 (2 open) [5].

BARD1 Loss is an inclusion criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain BARD1 Loss and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

BARD1 is altered in 1.6% of squamous cell lung carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BARD1 Loss and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [5].

BARD1 is altered in 1.42% of leiomyosarcoma patients with BARD1 Loss present in 0.59% of all leiomyosarcoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.13% of multiple myeloma patients with BARD1 Loss present in 0.49% of all multiple myeloma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.01% of mature T-cell and NK-cell non-hodgkin lymphoma patients with BARD1 Loss present in 0.31% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 is altered in 2.71% of bladder carcinoma patients with BARD1 Loss present in 0.2% of all bladder carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.49% of malignant gastric neoplasm patients with BARD1 Loss present in 0.13% of all malignant gastric neoplasm patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BARD1 is altered in 1.5% of malignant esophagogastric neoplasm patients with BARD1 Loss present in 0.05% of all malignant esophagogastric neoplasm patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BARD1 is altered in 1.42% of malignant ovarian epithelial tumor patients with BARD1 Loss present in 0.05% of all malignant ovarian epithelial tumor patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BARD1 is altered in 1.0% of invasive breast carcinoma patients with BARD1 Loss present in 0.04% of all invasive breast carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.8% of glioma patients with BARD1 Loss present in 0.03% of all glioma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 is altered in 1.71% of malignant central nervous system neoplasm patients with BARD1 Loss present in 0.03% of all malignant central nervous system neoplasm patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 is altered in 0.74% of ampulla of vater carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BARD1 is altered in 1.52% of anal carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BARD1 Loss and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

BARD1 is altered in 0.2% of B-cell non-hodgkin lymphoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.13% of bile duct adenocarcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BARD1 is altered in 1.17% of biliary tract carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BARD1 is altered in 1.13% of cholangiocarcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BARD1 is altered in 2.21% of colorectal adenocarcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BARD1 is altered in 0.45% of diffuse large B-cell lymphoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 Loss is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 Loss is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 is altered in 1.37% of low grade ovarian serous adenocarcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 is altered in 2.21% of malignant intestinal neoplasm patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BARD1 is altered in 1.34% of malignant mesothelioma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

BARD1 is altered in 3.31% of malignant small intestinal neoplasm patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BARD1 Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 is altered in 0.8% of medulloblastoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 is altered in 0.31% of neuroblastoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 Loss is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 Loss is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BARD1 Loss and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

BARD1 Loss is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 is altered in 0.47% of renal cell carcinoma patients [4].

BARD1 Loss is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BARD1 Loss is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 Loss and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BARD1 Loss is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BARD1 Loss and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

BARD1 Loss is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BARD1 Loss and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].